[Utility of the

Carlota de Miguel Barbero, Elvira Gea Rodríguez, Francesc Garcia Cuyàs

Abstract readEnglish Abstract

In one paragraph

Article in Revista espanola de salud publica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carlota de Miguel BarberoEscuela Internacional de Doctorado; Universidad de Andorra. Andorra.

Elvira Gea RodríguezEscuela Internacional de Doctorado; Universidad de Andorra. Andorra.

Francesc Garcia CuyàsEscuela Internacional de Doctorado; Universidad de Andorra. Andorra.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSince 2003, the National Cancer Institute (NCI) of the United States of America has been one of the world leaders in classifying adverse effects (AEs). Currently, smartphones allow, among many other things, the monitoring of these AEs of chemotherapy from home to improve the safety and quality of life of patients. The aim was to perform a descriptive comparative analysis of the AEs content of the

methodsThe

resultsThe CTCAE v5 (collects 837 AEs), where two hundred and twenty-five are signs and symptoms. The NCI classifies fifty-five signs and symptoms as the most recurrent, and the SEOM sixteen, of which fifteen coincide with the NCI. The

conclusionsThe

Indexed as

Antineoplastic AgentsMobile ApplicationsNeoplasmsHumansPatient ParticipationQuality of LifeSpainUnited StatesAntineoplastic AgentsCancerChemistryClinical OncologyEmpowerment for healthMobile ApplicationsNursingSpainTelemedicineToxicity

Identifiers

PMID38088092

PMCPMC11566884

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.